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Abstract
Background A higher incidence of lentigo maligna (LM) recurrences on the nose was previously observed in our cohort
after non-surgical treatment.
Objectives To determine histological parameters that might be related to the previously observed higher incidence of
LM recurrences on the nose after non-surgical treatment.
Methods We randomly selected 22 surgical specimens of LM on the nose and 22 on the cheek. Histopathological anal-
ysis was performed on haematoxylin and eosin stained and microphthalmia transcription factor immunohistochemically
stained slides. The number of pilosebaceous units (PSU) per mm, maximum depth of atypical melanocytes along the skin
appendages and maximum depth of the PSU itself were determined.
Results The nose had a signiﬁcantly higher density of PSU than the cheek. The atypical melanocytes extended deeper
along the PSU on the nose with a mean (SD) depth of 1.29 mm (0.48) vs. a mean depth of 0.72 mm (0.30) on the cheek
(P < 0.001). The maximum depth of the PSU on the nose was greater than on the cheek, mean (SD) depth of 2.28 mm
(0.41) vs. 1.65 mm (0.82) (P = 0.003).
Conclusions The higher recurrence risk of LM on the nose after non-surgical treatment that we previously observed in
our cohort is most likely based on a higher density of atypical melanocytes and also their deeper extension into the folli-
cles. These results shed more light on our previous ﬁndings and learn that anatomical location is relevant for the risk of
recurrence of LM after non-surgical treatment.






Lentigo Maligna (LM) is a subtype of melanoma in situ, and
although surgical excision is the treatment of first choice, non-
surgical treatment options are gaining more interest.1–3 Deciding
on the best individual treatment can be guided by the age of the
patient, comorbidities, size and location of the lesion.
In a previous publication, we introduced a non-surgical com-
bination treatment of ablative laser therapy followed by topical
application of imiquimod 5% cream.4 Recently, we found six
local recurrences in our cohort of 35 patients.5 Five of the six
recurrences occurred on the nose (out of a total of 15 treated
LM on the nose).
We argue that the following factors may contribute to a
higher risk of LM recurrence on the nose after non-surgical
treatment than on other anatomic locations. First, the down-
ward extension of atypical melanocytes along the pilosebaceous
units (PSU) may be an important factor. Non-surgical treat-
ments mainly target the epidermis, while atypical melanocytes
residing along the PSU may not be completely cleared. It is
known that the atypical melanocytes of melanomas in the head
and neck region tend to extend much deeper along the hair folli-
cles than in other regions.6 However, there are currently no data
available for LM comparing the depth of atypical melanocytes
along the PSU for different facial regions, or the nose in particu-
lar. Second, the density of the PSU may be highly relevant. It is
known that the PSU density varies for different anatomic loca-
tions, with the nose having the highest follicle density of the†These authors contributed equally to this work.
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body.7,8 We hypothesize that the recurrence risk of LM after
non-surgical treatment may be higher for the nose than for other
facial regions, because of a higher PSU density that may harbour
a considerably greater load of atypical melanocytes in deeper
parts of the appendages. Third, the maximum depth of the PSU
itself may be of importance since this allows the atypical melano-
cytes to penetrate even deeper.
The aims of our study were to determine whether the PSU
density, the maximum downward extension of atypical melano-
cytes along the PSU, and the maximum depth of the PSU itself
differed between LM on the nose and LM on the cheek.
Materials and methods
Patient selection
Data on all patients who had undergone staged surgical excision
for primary LM on the nose or cheek (most common location of
LM) at the Erasmus Medical Center between January 2001 and
December 2015 were obtained using Sympathy 2.8, a program of
our pathology department that is linked to PALGA (Dutch
Pathology Registry).
Inclusion and exclusion criteria
Exclusion criteria were: unavailability of the slides and corre-
sponding formalin-fixed paraffin embedded (FFPE) tissue
blocks, and presence of invasive melanoma. We decided to only
use excision specimens and exclude (small) diagnostic biopsies
in order to obtain adequate material for a thorough analysis and
an accurate measurement of our study parameters.
SPSS Statistics 21 was used to perform random number selec-
tion and the patient numbers were put in a random order. Two
lists were created, one for the nose and one for the cheek.
The corresponding surgical specimens were collected and eli-
gibility for inclusion was determined starting at the top of each
list, until 22 samples of each group were included (based on the
sample size calculation below). Eligibility was based on
histopathological review of haematoxylin and eosin (HE) stained
slides of the surgical specimens, acquired from the pathology
archive of the Erasmus MC. Specimens were not eligible if slides
were cut tangential, or if there was a high presence of scar tissue
(causing loss of PSU). A central slide was selected from each sur-
gical specimen. For some slides, there was no tissue left in the
corresponding FFPE block, or there was no LM left after cutting
the initial HE slides. Those samples had to be excluded as well,
because they could not be used for immunohistochemical stain-
ing.
Histopathological analysis
Blank slides were cut from the selected corresponding FFPE
blocks at 4 lm, deparaffinized and immunohistochemically
stained for microphthalmia transcription factor [MITF; mouse
monoclonal, Ventana, clone C5/D5, 790-4367 (ready to use)],
using the Ventana Benchmark Ultra stainer (Ventana Medical
Systems, Tucson, AZ, USA). The staining procedure included
pre-treatment with CC1 (Cell Conditioner 1, pH8,4) at 95 °C
for 64 min, followed by primary antibody incubation at 36 °C
for 16 min. Staining was visualized using the Ventana Ultraview
Universal Alkaline Phosphatase Red Detection Kit (760-501).
The Ventana Amplification Kit (760-080) was used, counter-
staining was performed with haematoxylin. Normal skin was
used as a positive control. MITF is a nuclear stain specific for
melanocytes, and the most useful immunohistochemical stain-
ing to detect single epidermal melanocytes.9 With MITF, the
nuclear polymorphism of melanocytes, which is characteristic
for LM, can be demonstrated as well, and these atypical mela-
nocytes can be distinguished from the small pre-existent mela-
nocytes found in the hair follicle, especially those in the hair
bulb.
Study outcomes
The following parameters were scored: number of PSU per epi-
dermal mm, maximum depth of downward extension of atypical
melanocytes along the skin appendages and maximum depth of
the PSU itself.
As the discrimination between vellus, indeterminate and ter-
minal hairs is sometimes difficult because of the one level view
of the slides, and as LM extends down into both vellus and dee-
per hair follicles, this distinction was not made. The total num-
ber of PSU, based on the presence of at least a part of the
pilosebaceous unit (i.e. infundibulum, isthmus, bulb or seba-
ceous glands assumed to belong to one PSU) was scored. The
number of PSU was then calculated per linear mm epidermis in
one horizontal dimension. We also measured the deepest point
of any of the PSU, and the maximum depth of atypical melano-
cytes along the skin appendages from the granular layer. If the
extension was deeper in an appendage other than a PSU (i.e.
sweat gland in one case), then this was counted as the maximum
depth.
Statistical analysis
A sample size of 22 patients per group was estimated to provide
80% power to detect a difference in density of approximately
600 follicles (per cm2),8 and an estimated difference of
0.6 mm (SD 0.7 mm) in depth of atypical melanocytes along
the PSU and depth of the PSU itself, with a two-sided type I
error level of 5%. A t-test for unpaired samples was used. In
order to provide enough statistical power for all endpoints, the
largest group size was chosen.
Normality of the variables was tested using a Shapiro–Wilk
test. Data that were normally distributed were summarized with
means and standard deviations (SD), and data that were not
normally distributed, with medians and interquartile ranges.
Differences between the nose and cheek group for normally dis-
tributed variables were analysed using a t-test for independent
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samples, and for not normally distributed variables using a
Mann–Whitney U-test.
To calculate the relative extension of atypical melanocytes
down the PSU, the extension of atypical melanocytes along the
PSU was divided by the depth of the PSU itself. P-values less
than or equal to 0.05 were considered statistically significant.
Additional false discovery rate control did not require signifi-
cance level adjustment.10 Statistical analysis of data was per-
formed using SPSS Statistics 21.
Results
Between January 2001 and December 2015, 122 patients were
diagnosed with a LM on the nose and 315 with LM on the cheek.
Of the 122 LM on the nose, 54 slides or blocks were unavailable,
13 had an invasive component, and 16 were biopsies. Of the 315
LM on the cheek, 103 slides or blocks were unavailable, 23 had
an invasive component and 58 were biopsies. After exclusion of
these cases, eligibility was assessed until 44 LM cases were ran-
domly selected; 22 located on the nose and 22 located on the
cheek.
The mean (SD) age in the nose group was 76 years (14) and
in the cheek group, 73 years (13). Gender distribution in the
nose group was 14 female, 8 male; and in the cheek group, 15
female and 7 male.
Number of PSU per mm (density)
The median number of PSU was significantly higher on the nose
than on the cheek (Table 1).
Maximum depth of atypical melanocytes along the PSU
The mean maximum depth of atypical melanocytes along the
PSU was greater on the nose than on the cheek (Table 1), with a
mean nose vs. cheek difference of 0.57 mm (95% CI, 0.33–0.82).
Maximum depth of PSU
The mean maximum depth of the PSU itself was greater on the
nose than on the cheek (Table 1), with a mean nose vs. cheek
difference of 0.63 mm (95% CI, 0.23–1.03).The atypical melano-
cytes extended, on average, 57% down the PSU on the nose and
49% down the PSU on the cheek (nose vs. cheek difference, 8%
[95% CI, 5 to 20]; P = 0.237).
Figures 1–4 show histological images of HE and MITF stains
of the downward extension of atypical melanocytes along the
PSU and an example of occasional extension along sweat glands.
Discussion
Our study shows that both the density of the PSU, and the maxi-
mum downward extension of atypical melanocytes along the
PSU are higher on the nose than on the cheek. This results in a
considerably higher load of atypical melanocytes in deeper parts
of the appendages, and may explain why LM recurrences
occurred almost exclusively on the nose after our non-surgical
treatment method.5
The maximum absolute depth of the PSU itself was found to
be greater on the nose than the cheek, while we did not find a
statistically significant difference in the ratio of extension of
atypical melanocytes down the PSU between the nose and the
cheek. This suggests that the melanocytes extended deeper on
the nose than the cheek, simply because the PSU are deeper on
the nose, and that there seems to be no intrinsic difference in
behaviour of atypical melanocytes between these two sites.
To the best of our knowledge, anatomic location has not yet
been evaluated as a potential prognostic factor for recurrences of
LM after non-surgical treatments. Gautschi et al. assessed the
maximal epidermal depth of the melanocytes (this was usually
the maximal depth along the hair follicle), as well as follicle
involvement (affected vs. not affected) as potential risk factors
for LM recurrence after imiquimod monotherapy, but did not
find statistically significant differences.11 However, the authors
did not specify the different anatomical facial regions (only
‘head’ or ‘other locations’), which could explain the difference
with the results found in this study. A factor that is considered
to be a strong predictor of LM recurrence is melanocyte
Table 1 Difference between the nose and the cheek
Variables Nose Cheek P-value
Number of PSU/mm [median (IQR)] 1.84/mm (1.53–2.63) 1.45/mm (1.07–1.64) 0.001
Maximum downward extension of atypical melanocytes
along the PSU [mean (SD)]
1.29 mm (0.48) 0.72 mm (0.30) 0.001
Maximum depth of PSU itself [mean (SD)] 2.28 mm (0.41) 1.65 mm (0.82) 0.003
IQR, interquartile range; PSU, pilosebaceous units; SD, standard deviation.
Figure 1 Lentigo maligna; continuous proliferation of atypical
melanocytes along the dermo-epidermal junction. Clear extension
downward, along the hair follicle is shown. In the background, sev-
ere solar elastosis. Arrows point out atypical melanocytes (haema-
toxylin and eosin 1009).
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count,11,12 which is in accordance with the higher ‘load’ of atypi-
cal melanocytes we found in this study, although we did not
measure melanocyte count specifically. Powell et al. reported
that the development of an inflammatory reaction to imiquimod
was a strong predictor for therapeutic benefit, but did not find
any histological features of prognostic significance.13 Mora et al.
found that cumulative dose and treatment intensity of imiqui-
mod monotherapy was associated with tumour clearance.14
Unfortunately, specific anatomic locations (e.g. the nose) are not
mentioned in these previous publications.
A higher risk of recurrence on the nose after non-surgical
treatment may influence the choice of treatment for this loca-
tion. Either a surgical treatment can be chosen, which remains
the treatment of first choice for LM, or in specific cases, consid-
ering the good cosmetic and functional outcomes of non-surgi-
cal treatments, the latter should be adapted for this location. In
case of our combined ablative laser therapy followed by topical
imiquimod cream, both the laser and imiquimod treatment pro-
tocols could be adapted.
Two types of ablative lasers are generally used, the erbium-
doped yttrium aluminium garnet (Er:YAG) laser (2940 nm) and
the carbon dioxide (CO2) laser (10600 nm), both of which have
been used to treat LM in our study population. The Er:YAG laser
removes approximately 15–25 lm per pass, and the CO2 laser
approximately 100–150 lm per pass.15,16 On the nose, we found
a mean maximum depth of atypical melanocytes extending
along the PSU of 1.29 mm. To reach this depth, approximately
10 passes of the CO2-laser are needed, and many more using the
Er:YAG laser, which in addition would be hampered by bleeding,
since there is less coagulation with this type of laser.17,18 The
CO2 laser would be more efficacious in removing a higher load
of atypical melanocytes and has good coagulation enabling dee-
per ablation without bleeding complications. For these reasons,
we propose to use the CO2 laser as ablative laser for the treat-
ment of LM located on the nose. However, this has to be further
validated in future studies. Passes should be applied until all visi-
ble pigment has been cleared, keeping in mind that scarring
should be prevented.
Mora et al. showed that cumulative dose (>60 total applica-
tions) and treatment intensity (>5 applications per week) of imi-
quimod as monotherapy affects tumour clearance.14 The
findings of Kirtschig et al. also suggest that a higher treatment
intensity of daily applications for 12 weeks may improve the
efficacy of imiquimod.19 It should be taken into account that
prolonged imiquimod treatment will significantly enhance the
patients’ discomfort. In our treatment protocol, we therefore
reduced imiquimod applications to 6 weeks (five times per
week), because the major part of the LM melanocytes were
removed by laser ablation. Also, since the epidermis and reticu-
lar dermis are removed, deeper penetration of imiquimod is
enabled and it is delivered closer to the target cells (the dermal
dendritic cells).
Based on the findings with imiquimod monotherapy, it is
conceivable that extending the duration of imiquimod treatment
would achieve better tumour clearance, and this may be consid-
ered for LM on the nose, in case too many laser passes are
expected to lead to a high risk of scarring.
A limitation of our study is that we could only revise verti-
cal but not horizontal sections, because the surgical materials
were treated according to the standard protocols with respect
to examining LM and resection margins. Therefore, we are
limited to a one-dimensional quantification of the PSU
Figure 2 Very deep extension along pilosebaceous units. Arrows
point out atypical melanocytes (haematoxylin and eosin 509).
(a) (b)
Figure 3 (a, b) Microphthalmia transcription factor (MITF)
immunohistochemistry, emphasizing the number of continuous
atypical melanocytes extending downward. The positive staining
cells in the stroma are macrophages (a) MITF 509, (b) MITF 1009.
Figure 4 Microphthalmia transcription factor (MITF) immunohis-
tochemistry. In one of the samples, the downward growth along
the sweat glands was even deeper than along the pilosebaceous
units (MITF 1009).
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density. Also, with our method, we were limited to two-
dimensional sections, while sometimes stereology or confocal
laser scanning can be used to estimate three-dimensional char-
acteristics and allow for better understanding of the distribu-
tion.20,21 However, since the aim of our study was to find a
difference between the nose and cheek regions, and both were
measured in a similar way, this would not have influenced our
conclusions. Another limitation is the use of a different popu-
lation to determine the histological parameters (surgical
patients) than the cohort on which our hypothesis was based
(laser and imiquimod patients).
In summary, we conclude that the higher recurrence risk of
LM on the nose after non-surgical treatment is most likely based
on the higher load of atypical melanocytes in deeper parts of the
appendages. This higher load is a result of a higher PSU density
on the nose, a deeper follicular extension of atypical melanocytes
and a greater absolute depth of the PSU. This should be taken
into account when making a choice of treatment for this specific
location.
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